Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.48 |
| ▸ | SSTR4 | P31391 | 4/20 | 0.48 |
| ▸ | SSTR1 | P30872 | 3/20 | 0.48 |
| ▸ | STS | P08842 | 1/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.45 |
| ▸ | FEN1 | P39748 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 2/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4509555 | 0.93 | SCN9A (0.54) | RBP4SSTR4SSTR1SCN9AALOX5AP | |
| SCHEMBL22265811 | 0.93 | KDM4E (0.54) | RBP4KDM4EPKMGPR119SSTR4 | |
| SCHEMBL27157756 | 0.87 | RBP4 (0.54) | RBP4KDM4EPKMGPR119SCN9A | |
| SCHEMBL20744476 | 0.87 | RBP4 (0.54) | RBP4KDM4EPKMGPR119SCN9A | |
| SCHEMBL3113872 | 0.86 | RBP4 (0.71) | RBP4KDM4EPKMGPR119SCN9A | |
| SCHEMBL18728698 | 0.85 | RBP4 (0.48) | RBP4KDM4EPKMGPR119STS | |
| SCHEMBL18728701 | 0.85 | RBP4 (0.48) | RBP4KDM4EPKMGPR119STS | |
| SCHEMBL25310147 | 0.84 | RBP4 (0.60) | RBP4KDM4EPKMSSTR4SSTR1 | |
| SCHEMBL20744399 | 0.84 | RBP4 (0.52) | RBP4KDM4EPKMGPR119SCN9A | |
| SCHEMBL25310149 | 0.84 | RBP4 (0.60) | RBP4KDM4EPKMSSTR4SSTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4474017-A2 | NEW HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-12-11 | — | — | EP | disclosed |
| EP-3837263-B1 | NEW HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2024-07-03 | — | — | EP | disclosed |
| US-20090325956-A1 | Aromatic amine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325956-A1 | Aromatic amine derivative and use thereof | SCD, SCD5, SMS | RBP4 1872/4885KDM4E 249/4885PKM 1263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.